NEW YORK (GenomeWeb) – Grifols has garnered a CE-IVD mark for ID Core XT, a bead array-based assay for molecular blood group typing, the company said this week.

Barcelona-based Grifols, which sells plasma medicines, diagnostics, and hospital pharmacy products, believes the certification of ID Core XT as an in vitro diagnostic will allow it to reach more European blood donor services and blood transfusion services at a time when they are increasingly adopting new technologies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.